| Name | Title | Contact Details |
|---|
TriHealth is the healthcare system that formed as a partnership between Good Samaritan Hospital and Bethesda Hospital, Inc. Through acute care hospitals and more than 80 locations, TriHealth provides a wide range of clinical, educational, preventive an...
Access Plans USA, Inc. (Access Plans) develops and distributes health care programs for individuals, and employer groups. Its products and programs include health insurance plans and non-insurance health care discount programs.
Amedisys is a leading home health and hospice care company focused on bringing home the continuum of care. We deliver personalized home health and hospice care to thousands of patients and their families, in the comfort of their own homes. Our care teams deliver personalized home health and hospice care to approximately 380,000 patients each year. Amedisys is a post-acute care partner to more than 2,233 hospitals and 61,900 physicians across the country. We provide the care that is best for our patients, whether that is home-based recovery and rehabilitation after an operation or injury, care focused on empowering them to manage a chronic disease, palliative care for those with a terminal illness, or hospice care at the end of life. Amedisys is a recognized innovator, being one of the first in the industry to equip its clinicians with point-of-care laptop technology and referring physicians with an internet portal that enables real-time coordination of patient care seamlessly. Amedisys also has the industry`s first-ever nationwide Care Transitions program, designed to reduce unnecessary hospital readmissions through patient and caregiver health coaching and care coordination, which starts in the hospital and continues throughout completion of the patient`s home health plan of care.
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III
Zeltiq Aesthetics Inc is a Pleasanton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.